Importantly, a potent PLK1 inhibitor, volasertib (BI6727), has been recently approved for the treatment of acute myeloid leukemia and would be a promising therapeutic agent against palbociclib-resistant breast cancer [33,34]. This evidence concerns the gene PLK1 and breast carcinoma.